THOUSAND OAKS, Calif. , Nov. 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN - News) today announced that the European Commission (EC) has approved a variation to the marketing authorization for ...
THOUSAND OAKS, Calif., June 18, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating Vectibix ® (panitumumab) and best supportive care (BSC) met its primary ...
Lumakras plus Vectibix improved overall survival and response rates in KRAS G12C-mutated metastatic colorectal cancer, despite not achieving statistical significance. The combination showed a 30% ...
2-month benefit for progression free survival in 2nd-line Vectibix is challenger for colon cancer drug Erbitux BERLIN, Sept 22 (Reuters) - Amgen's colon cancer drug Vectibix helped patients live ...
Lumakras and Vectibix combination approved for KRAS G12C-mutated mCRC after specific chemotherapy regimens. CodeBreaK 300 trial showed improved progression-free survival with Lumakras/Vectibix ...
THOUSAND OAKS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that Vectibix (panitumumab), administered in combination with FOLFOX (an ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
THOUSAND OAKS, Calif., April 18 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a new biomarker analysis of the pivotal Phase 3 ...
The colon cancer Vectibix did not improve survival in head-and-neck cancer, maker Amgen announced this morning. Shares dropped 2% in early morning trading. The result is disappointing because Vectibix ...
Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion to extend the marketing ...
THOUSAND OAKS, Calif., (Sept. 27, 2006) – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Vectibix TM (panitumumab) following priority review.
Amgen (AMGN) announced that new data from the phase II PEAK study and the phase III PRIME study were presented at the 2015 American Society of Clinical Oncology (ASCO) gastrointestinal cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results